Advertisement

Life-Sciences-Europe.com
The European Life Sciences Web Portal
This is a free web portal for the life sciences in Europe and Israel... » read more
- SHS: Final Closing Fund VI at €270m, after €220m 1st Close (2023-09-13)
> The German Private Equity Investor SHS Capital has completed the Final Closing of its sixth fund generation > The targeted fund volume of EUR 200 million could significantly be overachieved with ca. EUR 270 million and is more than doubling the predecessor fun... - Lauxera Capital Partners Invests €17m in BioLamina AB (2023-09-12)
> Founded in 2009 and based in Sundbyberg, Sweden, BioLamina’s recombinant human laminin proteins are revolutionizing the development and manufacturing of regenerative cell therapeutics and disease models derived from both stem cells and primary cells > Lauxera ... - Kuano Raises £1.8M Seed Round for Quantum Drug Discovery (2023-09-12)
> Led by Mercia Ventures, investors include ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and Angel investors > Funds will enable further growth and validation of Kuano’s quantum simulation platform for enzyme targeted drug discovery ... - Bastion Therapeutics Secures $840k to Develop Tregs (2023-09-12)
Bastion Therapeutics secures $840,000 in launch financing to develop advanced Treg therapeutics for inflammatory disorders and autoimmune diseases Bastion Therapeutics (“Bastion”), a preclinical biotechnology company focused on restoring immune balance, has se... - ICR Acquires Consilium Strategic Communications (2023-09-12)
> Consilium to combine with ICR’s US-based healthcare practice, providing clients with seamless integrated support for strategic communications and investor engagement across US, Europe and Asia > Combined practice includes more than 100 team members and nearly ... - Sandoz to Commercialise Samsung’s Biosimilar Ustekinumab (2023-09-11)
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering > Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europ... - Orbit Discovery & Orano Med: Drug Discovery Collaboration (2023-09-11)
Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 (212Pb) Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit”, a leader in the discovery of therapeutic peptide hits, today announced that they have entered into a collaborati... - Immatics & Moderna: Strategic Collaboration; $120m Upfront (2023-09-11)
> Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules > Companies to leverage Immatics’ XPRESIDENT® target discovery platform and Moderna’s mRNA technology for the development of novel cancer vaccin... - Verge Genomics & Alexion: AI-enabled Drug Discovery (2023-09-08)
> Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M > The collaboration is the second with a leading global pharmaceutical company and shows the unique scalability of the CONVERGE™ platform for t... - Mariana Oncology: $175m Series B Led by Deep Track & Forbion (2023-09-07)
> Financing round led by Deep Track Capital and Forbion with participation from a syndicate of leading biotechnology investors > Proceeds to support advancement of novel portfolio of precision, next-generation radiopharmaceuticals and transition into a clinical-...
Life-Sciences-Europe.com is your doorway to the European life sciences!
[LSE] provides free, up-to-date and structured access to
– News
– Products
– Persons
– Organisations
– Financings
– Collaborations
in Europe and Israel.
Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSE] is 100% Made in Germany!
» Start here with the latest News!Advertisement

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top